Ioannis Zerdes, Clinical Fellow in Medical Oncology and Associate Professor at Karolinska Comprehensive Cancer Center, shared on LinkedIn:
“Glad to share this new article from the International Immuno-Oncology Biomarker Working Group, to which I contributed as a co-author, in The Lancet Oncology.
Our work reviews the emerging role of tumour-infiltrating lymphocytes (TILs) in breast radiotherapy and discusses how TILs could be integrated into future radiation oncology trials and, ultimately, clinical practice.
Many thanks to the entire team for the excellent leadership, collaboration, and collective effort behind this work.
This publication is part of a series of 3 papers from the WG, published in the same issue, alongside 2 studies featuring digital pathology and AI-based approaches for TIL assessment in breast cancer, providing an exciting step toward more standardized and clinically applicable immune biomarkers in breast cancer.”
Title: Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group
Authors: Jetske L B Gunster, Trine Tramm, Melanie Machiels, Sandra Demaria, Silvia C Formenti, Alex de Caluwe, Frances Duane, Jonathan Klein, Daniel Sur, Navita Somaiah, Eileen Rakovitch, Katarzyna J Jerzak, Fang-I Lu, Crispin T Hiley, Muriel Brackstone, Anna Ehinger, Sai K Maley, Balazs Acs, Ioannis Zerdes, Demet Ozcan, Andrey Khramtsov, Eduardo Salido, Thomas G Papathomas, Priyanka Sharma, Shane Stecklein, Galina Khramtsova, Zsuzsanna Horvath, Daniel Markov, Alexandros Hardas, Jose Fernando do Prado Moura, Ana Ramirez, Wendy A Woodward, Abirami Sivapiragasam, Carsten Denkert, Stefan Michiels, Sherene Loi, Philip Poortmans, Robert W Mutter, Roberto Salgado, William T Tran on behalf of the International Immuno-Oncology Biomarker Working Group.
You can also read:
Artificial Intelligence Brings TILs Into the Digital Era
